Zymeworks Inc. (ZYME)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS98985Y1082
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Zymeworks Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:42. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 04 Mar 2027 16:00 | 0.20 | — | — | Upcoming |
| 09 Nov 2026 16:00 | 2.19 | 2.28 | +4.3% | Beat |
| 06 Aug 2026 16:00 | -0.58 | -0.62 | -7.7% | Miss |
| 07 May 2026 16:00 | -0.10 | -0.59 | -484.3% | Miss |
| 02 Mar 2026 06:00 | -0.32 | -0.55 | -70.6% | Miss |
| 06 Nov 2025 16:00 | -0.32 | -0.26 | +17.8% | Beat |
| 07 Aug 2025 16:00 | -0.47 | 0.03 | +106.4% | Beat |
| 08 May 2025 16:00 | -0.70 | -0.30 | +57.3% | Beat |
| 05 Mar 2025 16:00 | -0.09 | -0.31 | -236.2% | Miss |
| 31 Oct 2024 16:00 | -0.41 | -0.39 | +4.5% | Beat |
| 01 Aug 2024 16:00 | -0.31 | -0.49 | -58.9% | Miss |
| 02 May 2024 16:00 | -0.29 | -0.42 | -43.8% | Miss |
| 06 Mar 2024 16:00 | -0.44 | -0.20 | +54.8% | Beat |
| 07 Nov 2023 16:00 | -0.47 | -0.41 | +13.0% | Beat |
| 10 Aug 2023 16:00 | -0.47 | -0.76 | -61.0% | Miss |
| 08 May 2023 16:00 | -0.54 | -0.36 | +33.3% | Beat |
| 07 Mar 2023 16:00 | 3.11 | 4.65 | +49.3% | Beat |
| 08 Nov 2022 16:00 | -0.97 | -0.72 | +26.0% | Beat |
| 04 Aug 2022 16:00 | -0.94 | -0.97 | -2.8% | Miss |
| 04 May 2022 16:00 | -0.76 | -1.19 | -57.4% | Miss |
| 24 Feb 2022 16:00 | -1.13 | -0.76 | +32.8% | Beat |
| 03 Nov 2021 16:00 | -1.08 | -1.17 | -8.1% | Miss |
| 04 Aug 2021 16:00 | -1.04 | -1.31 | -26.0% | Miss |
| 05 May 2021 16:00 | -1.05 | -0.87 | +16.9% | Beat |
| 24 Feb 2021 16:00 | -1.25 | -0.74 | +40.6% | Beat |
| 03 Nov 2020 16:00 | -0.99 | -1.43 | -45.0% | Miss |
| 05 Aug 2020 16:00 | -0.87 | -0.77 | +11.8% | Beat |
| 07 May 2020 17:00 | -1.04 | -0.64 | +38.7% | Beat |
| 02 Mar 2020 16:00 | -0.88 | -1.66 | -88.6% | Miss |
| 05 Nov 2019 16:00 | -0.74 | -0.70 | +5.8% | Beat |
| 02 Aug 2019 17:00 | -0.60 | -0.86 | -44.3% | Miss |
| 02 May 2019 17:00 | -0.52 | -0.43 | +16.9% | Beat |
| 06 Mar 2019 17:00 | 0.53 | 0.29 | -45.6% | Miss |
| 06 Nov 2018 16:00 | -0.64 | -0.59 | +8.4% | Beat |
| 01 Aug 2018 08:00 | -0.33 | -0.22 | +33.9% | Beat |
| 01 May 2018 16:00 | -0.67 | -0.83 | -23.9% | Miss |
| 14 Mar 2018 16:00 | -0.03 | 1.28 | +4,589.7% | Beat |
| 08 Nov 2017 16:00 | -0.57 | -0.64 | -12.1% | Miss |
| 09 Aug 2017 06:00 | -0.54 | -0.38 | +30.5% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 106M | +38.9% | -81.1M | -76.6% | -1.08 | +33.3% | -35.4M |
| 2024 | 76.3M | +0.4% | -122.7M | -160.8% | -1.62 | +5.8% | -113.1M |
| 2023 | 76M | -81.6% | -118.7M | -156.1% | -1.72 | -190.5% | -122.4M |
| 2022 | 412.5M | — | 124.3M | 30.1% | 1.90 | — | 131M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 30.00 | 31.97 | 25.89 | 25.95 | -12.42% | 5,238,421 | |
| 02 Nov 2026 – 06 Nov 2026 | 28.69 | 31.49 | 28.27 | 29.63 | +3.57% | 6,873,400 | |
| 26 Oct 2026 – 30 Oct 2026 | 28.36 | 29.50 | 27.59 | 28.61 | +1.38% | 6,479,000 | |
| 19 Oct 2026 – 23 Oct 2026 | 25.06 | 28.97 | 25.06 | 28.22 | +12.74% | 8,369,800 | |
| 12 Oct 2026 – 16 Oct 2026 | 25.56 | 26.21 | 24.60 | 25.03 | -2.95% | 7,174,600 | |
| 05 Oct 2026 – 09 Oct 2026 | 25.37 | 27.02 | 25.00 | 25.79 | +2.54% | 5,981,800 | |
| 28 Sep 2026 – 02 Oct 2026 | 25.94 | 28.26 | 25.04 | 25.15 | -5.17% | 5,613,700 | |
| 21 Sep 2026 – 25 Sep 2026 | 26.84 | 27.89 | 26.14 | 26.52 | -0.19% | 3,523,900 | |
| 14 Sep 2026 – 18 Sep 2026 | 26.80 | 27.86 | 25.81 | 26.57 | +1.26% | 4,376,500 | |
| 08 Sep 2026 – 11 Sep 2026 | 28.93 | 28.93 | 26.03 | 26.24 | -10.11% | 2,454,300 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44 (opens in a new tab) Benzinga · 11 Nov 2026 14:24
- TD Cowen Maintains Buy on Zymeworks, Raises Price Target to $39 (opens in a new tab) Benzinga · 10 Nov 2026 13:16
- Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36 (opens in a new tab) Benzinga · 10 Nov 2026 11:58
- HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56 (opens in a new tab) Benzinga · 10 Nov 2026 07:42
- Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates (opens in a new tab) Zacks · 09 Nov 2026 22:35
- Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results (opens in a new tab) 09 Nov 2026 21:05
- Zymeworks Raises FY2026 Sales Guidance from $278.000M-$292.000M to $337.000M-$351.000M vs $302.672M Est (opens in a new tab) Benzinga · 09 Nov 2026 18:21
- Zymeworks Q3 EPS $2.28 Beats $2.18 Estimate, Sales $256.460M Beat $228.465M Estimate (opens in a new tab) Benzinga · 09 Nov 2026 17:19
- Zymeworks (ZYME) Stock May Be Overvalued On Its New Lung Cancer Deal (opens in a new tab) Simply Wall St. · 04 Nov 2026 08:13
- Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal (opens in a new tab) Simply Wall St. · 04 Nov 2026 04:33
- Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth (opens in a new tab) Zacks · 29 Oct 2026 13:00
- Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside (opens in a new tab) MarketBeat · 27 Oct 2026 23:04
- How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal (opens in a new tab) Simply Wall St. · 26 Oct 2026 22:18
- Zymeworks stock surges on $813M Roche licensing deal (opens in a new tab) Investing.com · 23 Oct 2026 14:25
- Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones (opens in a new tab) MT Newswires · 23 Oct 2026 11:49
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 26.47 USD
- Market cap
- 1.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ZYME and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.